PPLPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.5
| Stock Code | PPLPHARMA | Market Cap | 21,401 Cr. | Current Price | 161 ₹ | High / Low | 241 ₹ |
| Stock P/E | 29.0 | Book Value | 58.2 ₹ | Dividend Yield | 0.09 % | ROCE | 12.4 % |
| ROE | 9.74 % | Face Value | 10.0 ₹ | DMA 50 | 170 ₹ | DMA 200 | 189 ₹ |
| Chg in FII Hold | -0.61 % | Chg in DII Hold | 0.79 % | PAT Qtr | 151 Cr. | PAT Prev Qtr | 196 Cr. |
| RSI | 47.0 | MACD | -5.26 | Volume | 40,94,856 | Avg Vol 1Wk | 57,50,649 |
| Low price | 148 ₹ | High price | 241 ₹ | PEG Ratio | 1.31 | Debt to equity | 0.12 |
| 52w Index | 13.9 % | Qtr Profit Var | 27.4 % | EPS | 5.39 ₹ | Industry PE | 29.2 |
📊 Analysis: PPLPHARMA is trading at ₹161, below both its 50 DMA (₹170) and 200 DMA (₹189), indicating short-term weakness. RSI at 47.0 is neutral, while MACD (-5.26) reflects mild bearish undertone. Volume is lower than the weekly average, suggesting reduced intraday participation. Fundamentals are moderate, with fair valuation compared to industry PE, but recent earnings decline limits upside momentum. Suitable for cautious intraday trades with strict stop-loss discipline.
💡 Optimal Buy Price: ₹158–161 (near support zone, risk-managed entry).
🎯 Profit-Taking Levels: ₹166–168 (first resistance), ₹172 (secondary resistance if momentum sustains).
🛡️ Stop-Loss / Loss Protection: ₹154 (below intraday support).
⏱️ If Already Holding: Exit near ₹166–168 if momentum stalls. If price sustains above ₹168 with strong volume, hold for ₹172. Exit immediately if price breaks below ₹154 with heavy selling pressure.
Positive
- EPS at ₹5.39 reflects profitability.
- ROCE (12.4%) and ROE (9.74%) show moderate capital efficiency.
- DII holding increased (+0.79%), reflecting domestic institutional support.
- PEG ratio at 1.31 suggests reasonable valuation relative to growth.
- Debt-to-equity ratio at 0.12 indicates low leverage risk.
Limitation
- Stock trading below both 50 DMA and 200 DMA indicates weak trend.
- Dividend yield at 0.09% offers negligible investor return.
- MACD negative, showing bearish undertone.
- Volume below weekly average reduces intraday momentum strength.
Company Negative News
- Quarterly PAT declined to ₹151 Cr. vs ₹196 Cr. previously.
- FII holding decreased (-0.61%), showing reduced foreign investor confidence.
Company Positive News
- Quarterly profit variation at +27.4% shows operational improvement despite lower PAT.
- DII holding increased (+0.79%), reflecting domestic institutional support.
Industry
- Industry PE at 29.2, close to PPLPHARMA’s 29.0, suggesting fair valuation.
- Pharmaceutical sector remains growth-oriented, supported by healthcare demand and innovation.
Conclusion
⚖️ PPLPHARMA presents moderate intraday potential with fair valuation but weak technicals. Entry near ₹158–161 with exit around ₹166–168 is advisable. If momentum sustains, ₹172 is achievable. Strict stop-loss at ₹154 ensures risk management. Suitable for cautious intraday traders.